ALK and breast carcinoma: Certain targets were enriched in specific cancer types as expected based on the clinical treatment landscape or tumor biology (eg, EGFR, MET, ROS1, MET, and ALK in NSCLC; or ERBB2, CDK4, CDK6, aromatase, and ER in breast cancer).